For additional information about our clinical trials, please contact us at firstname.lastname@example.org.
Voyager is beginning a Phase 2, placebo-controlled trial to assess its gene therapy program, VY-AADC, for the treatment of Parkinson’s disease. Twenty-four clinical trial sites (including neurosurgical and neurology patient referral sites) have been selected for participation in the Phase 2 trial.
A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson’s Disease With Motor Fluctuations
Recruiting. Enrolled patients between the ages of 40-75 who have been diagnosed with Parkinson’s disease for at least four years and have demonstrated responsiveness to dopaminergic therapy.
For more information about Voyager’s Phase 2 clinical trial with its gene therapy program VY-AADC for the treatment of Parkinson’s disease, please visit https://clinicaltrials.gov/ct2/results?cond=&term=+NCT03562494&cntry=&state=&city=&dist or email www.clinicaltrials.gov.